Will Health Insurers Inhibit Medical Progress?
Very few patients have noticed an epic struggle taking place among policy wonks, lobbyists, hedge fund managers and economists in the drug and insurance industries. Some want to describe the…
Amgen’s Right, ICER Cherry Picks Who Lives Or Dies
A lot of the health media was surprised that Amgen decided to criticize ICER before it released its draft decision about the price and access to new medicines for multiple myeloma…
As I See It: Setting New Goals, Dreaming New Dreams
A Boston-based think tank is currently developing policy proposals to measure the “effectiveness and value” of treatment options for a rare blood cancer called multiple myeloma. If you think this…